GWOXI Stem Cell Partners with Malaysia’s Cell 101 to Expand into the Asia-Pacific Regenerative Medicine Market
Signing ceremony (from left: Dr. Chuan-Feng Chiu, CEO of GWOXI Stem Cell; Dr. Ming-Hsi Chuang, Chairman of GWOXI Stem Cell; Dr. Dato Sivakumar Krishnan, Chairman of Cell 101; and Dr. Shorubben Chinetamby, CEO of Cell 101). Photo courtesy of GWOXI Stem Cell.
GWOXI Stem Cell (TPEx: 6704) today announced the signing of a Memorandum of Understanding (MOU) with Malaysia-based Cell 101 International Sdn Bhd, a company mainly focusing on regenerative medicine. Through this collaboration, the two companies aim to jointly expand their presence in the Asia-Pacific regenerative medicine market.
The two companies will jointly address unmet medical needs by applying mesenchymal stem cells (MSCs) and MSCs-derived exosomes in areas such as tissue regeneration and repair, healthcare and wellness, aesthetic medicine, and personalized care. By integrating clinical, manufacturing, and market resources, the two companies aim to establish a strategic alliance to advance regenerative medicine and cell therapy across the Asia-Pacific region.
Following the successful conclusion of the 2025 Taiwan–Malaysia Industrial Collaboration Summit yesterday (September 21 2025), Cell 101, together with the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) of Taiwan Ministry of Economic Affairs, visited GWOXI Stem Cell today to further strengthen Taiwan–Malaysia commercial collaboration.
GWOXI highlighted that Cell 101’s mission is “to improve human health and disease treatment through cell therapy.” Chairman Dr. Dato Sivakumar Krishnan and CEO Dr. Shorubben Chinetamby bring decades of expertise in preventive medicine and cell therapy. They have built extensive networks across government, industry, and academia throughout the Asia-Pacific region, and are committed to advancing personalized and preventive care, with core strengths in cell therapy and diagnostic technologies.
Headquartered in Malaysia, Cell 101 has established partnerships in Indonesia, Thailand, Singapore, and West Asia, and maintains close ties with the Association of Southeast Asian Nations (ASEAN) to continuously expand its presence in the Asia-Pacific market. In Kuala Lumpur and Penang, the company collaborates with multiple medical institutions to conduct clinical trials and provide healthcare services. Cell 101 has also set up a cGMP cell processing facility at the Taman Sains Selangor Technology Park in Petaling Jaya, which is currently undergoing certification.
GWOXI Stem Cell emphasized that it will leverage its proprietary manufacturing processes, regenerative medicinal products, and PIC/S GMP-compliant production capabilities as the foundation of this collaboration, combining them with Cell 101’s strong presence and network in the Southeast Asian healthcare ecosystem to accelerate the commercialization and market entry of innovative regenerative medicinal products and services—shortening the time for patients to access these novel treatments.
As the first Taiwanese pharmaceutical company conduct a unprecedented clinical trial involving the overseas shipment of stem cells for treatment, GWOXI holds over 120 patents covering stem cell therapy development, proprietary cell process, drug formulation, and stem cell-derived exosome massive production. Four stem cell medicines are currently in clinical development: GXNPC1® for chronic ischemic stroke (Phase III); GXCPC1® for knee osteoarthritis (Phase III), GXHPC1® for liver cirrhosis (Phase II); and GXIPC1® for diabetes mellitus (Phase I completed in Vietnam).
GWOXI Stem Cell Chairman Dr. Ming-Hsi Chuang stated that the Asia-Pacific region is one of the fastest-growing markets for regenerative medicine worldwide. According to Market Data Forecast, the Asia-Pacific regenerative medicine market is projected to grow at a compound annual growth rate (CAGR) of 28.9% from 2024 to 2033, with the stem cell therapy market segment expected to expand from approximately USD 4 billion in 2024 to USD 8.6 billion in 2032.
GWOXI Stem Cell will leverage its cell therapy products and PIC/S GMP-compliant manufacturing capabilities together with Cell 101’s regional healthcare networks to accelerate commercialization — Photo courtesy of GWOXI Stem Cell